Rewiring human cellular input-output using modular extracellular sensors.
暂无分享,去创建一个
Joshua N Leonard | Kelly A. Schwarz | Nichole M. Daringer | Taylor B Dolberg | Taylor B. Dolberg | Nichole M Daringer | J. Leonard | Kelly A Schwarz
[1] Eli J. Fine,et al. DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.
[2] Napoleone Ferrara,et al. VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.
[3] J. Wess,et al. Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.
[4] F. Peale,et al. Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.
[5] Xiaoliu Zhang,et al. Activation of Silenced Cytokine Gene Promoters by the Synergistic Effect of TBP-TALE and VP64-TALE Activators , 2014, PloS one.
[6] Morgan L. Maeder,et al. CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.
[7] Christopher M. Vockley,et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.
[8] Luke A. Gilbert,et al. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.
[9] A. Plückthun,et al. Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.
[10] B. Levine,et al. Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.
[11] Wendell A. Lim,et al. Cell-Based Therapeutics: The Next Pillar of Medicine , 2013, Science Translational Medicine.
[12] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[13] G. Barnea,et al. The genetic design of signaling cascades to record receptor activation , 2008, Proceedings of the National Academy of Sciences.
[14] A. Kortt,et al. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. , 1999, Protein engineering.
[15] Kelly A. Schwarz,et al. Modular Extracellular Sensor Architecture for Engineering Mammalian Cell-based Devices , 2014, ACS synthetic biology.
[16] Kelly A. Schwarz,et al. Engineering cell-based therapies to interface robustly with host physiology. , 2016, Advanced drug delivery reviews.
[17] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[18] M. Kalos,et al. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.
[19] J. P. Ferreira,et al. Tuning gene expression with synthetic upstream open reading frames , 2013, Proceedings of the National Academy of Sciences.
[20] O. Boyman,et al. Interleukin-2: Biology, Design and Application. , 2015, Trends in immunology.
[21] G. Majumdar,et al. Accessory cell-independent stimulation of human T cells by streptococcal M protein superantigen. , 1990, Journal of immunology.
[22] Russell M. Gordley,et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.
[23] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[24] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[25] Meagan E. Sullender,et al. Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.
[26] T. Copeland,et al. The P1' specificity of tobacco etch virus protease. , 2002, Biochemical and biophysical research communications.
[27] Alexandro E. Trevino,et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.
[28] B. Roth,et al. Generation of Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) Using Directed Molecular Evolution , 2010, Current protocols in neuroscience.
[29] Kole T. Roybal,et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.
[30] Jun Ma,et al. GAL4-VP16 is an unusually potent transcriptional activator , 1988, Nature.
[31] Martin Fussenegger,et al. Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis , 2015, Science Translational Medicine.
[32] Bo Kara,et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. , 2015, Regenerative medicine.
[33] Ron Weiss,et al. A platform for rapid prototyping of synthetic gene networks in mammalian cells , 2014, Nucleic acids research.
[34] Mauricio S. Antunes,et al. Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway , 2011, PloS one.
[35] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[36] C. Eigenbrot,et al. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. , 2004, Journal of molecular biology.
[37] M. Ultsch,et al. Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.